Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
We haven't written up this one. Yahoo Finance has the full story — the link below goes straight to it.
More in Health & Medicine
Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program
A new study showed that a prgrammed lysis approach cut mechanical separation energy by over 50 percent at pilot scale, widening the range of bioalternatives that can compete pricewise.
Horse or Newborn Baby? First 'I'm a Doctor' Moment; Clean Water Ruling
(MedPage Today) -- The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. Is this a horse or a newborn baby?
FDA suggests regulatory flexibility for assessing psychedelics
FDA regulators said they’re open to “innovative approaches” for studying the effects of psychedelic therapies, including the use of comparators other than placebo.
Piping Hot Drinks & Esophagus Cancer; Belching Disorder in GERD; Outbreak Sickens 22
(MedPage Today) -- People who consumed their hot beverages at a "very hot" temperature had a threefold higher risk for squamous cell carcinoma of the esophagus compared with those who drank them at a…
Chronic Interferon Exposure Linked to Immunosuppression in Cancer
A preclinical study uncovered a novel pathway that links chronic IFN-II exposure to mitochondrial dysfunction and ultimately immunosuppression in cancer, creating foundational insights that may point…
Guardians reliever Andrew Walters undergoes elbow surgery
Andrew Walters was a part of the 2024 playoff bullpen. Since that time, he's battled injuries on his road back to the majors.
- Andrew Walters, Guardians reliever, undergoes elbow surgery
- Surgery performed by Dr. Keith Meister in Texas
- Projected return-to-play timeline: 10-to-12 months